Quick Answer
Harmony Biosciences Holdings, Inc. reported Total Revenue of $868.45 million for fiscal year 2025.
Harmony Biosciences Holdings, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $868.45M +21.5% |
$714.73M +22.8% |
$582.02M +32.9% |
$437.86M +43.4% |
$305.44M +91.2% |
$159.74M +2564.6% |
| Revenue (ASC 606) | $868.45M +21.5% |
$714.73M +22.8% |
$582.02M +32.9% |
$437.86M +43.4% |
$305.44M +91.2% |
$159.74M +2564.6% |
| Net Income | $158.69M +9.1% |
$145.49M +12.9% |
$128.85M -29.0% |
$181.47M +424.5% |
$34.60M +193.6% |
-$36.94M +75.7% |
| Diluted EPS | $2.71 +8.0% |
$2.51 +17.8% |
$2.13 -28.3% |
$2.97 +412.1% |
$0.58 +123.4% |
-$2.48 +89.7% |
| Total Assets | $1.27B +27.3% |
$999.20M +23.1% |
$811.45M +20.4% |
$673.87M +55.5% |
$433.44M +1.5% |
$427.07M +300.2% |
| Cash and Equivalents | $752.50M +66.1% |
$453.00M +45.4% |
$311.66M +27.8% |
$243.78M +4.0% |
$234.31M +2.5% |
$228.63M +834.8% |
| Long-Term Debt | $143.66M -11.9% |
$163.02M -8.7% |
$178.57M -5.8% |
$189.65M -0.2% |
$189.98M -2.2% |
$194.25M +98.3% |
| Stockholders Equity | $870.22M +32.0% |
$659.15M +41.1% |
$466.99M +15.9% |
$402.84M +116.0% |
$186.51M +91.9% |
$97.18M +123.0% |
| R&D Expense | $189.59M +30.0% |
$145.82M +91.7% |
$76.06M +7.3% |
$70.89M +133.4% |
$30.37M +56.1% |
$19.45M -72.1% |
| Operating Income | $208.47M +9.2% |
$190.83M -0.6% |
$192.03M +59.8% |
$120.19M +37.3% |
$87.53M +415.3% |
$16.99M +111.6% |
| Gross Profit | $670.11M +20.1% |
$557.92M +21.1% |
$460.79M +30.0% |
$354.37M +41.8% |
$249.92M +89.3% |
$132.00M +2887.9% |
| Shares Outstanding | 57.73M +1.0% |
57.14M +0.7% |
56.77M -4.8% |
59.62M +1.3% |
58.83M +3.4% |
56.89M +630.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $239.46M | +28.7% | +19.4% |
| Revenue (ASC 606) | September 30, 2025 | $239.46M | +28.7% | +19.4% |
| Net Income | September 30, 2025 | $50.87M | +10.4% | +27.9% |
| Diluted EPS | September 30, 2025 | $0.87 | +10.1% | +27.9% |
| Total Assets | September 30, 2025 | $1.21B | +30.2% | +9.0% |
| Cash and Equivalents | September 30, 2025 | $647.00M | +67.0% | +18.5% |
| Long-Term Debt | September 30, 2025 | $148.51M | -11.5% | -3.2% |
| Stockholders Equity | September 30, 2025 | $835.12M | +39.9% | +8.0% |
| R&D Expense | September 30, 2025 | $54.96M | +116.5% | +9.6% |
| Operating Income | September 30, 2025 | $65.49M | +6.1% | +35.9% |
| Gross Profit | September 30, 2025 | $179.81M | +25.5% | +10.8% |
| Shares Outstanding | September 30, 2025 | 57.60M | +1.0% | +0.1% |
- Harmony Biosciences Holdings, Inc. reported Total Revenue of $868.45 million for fiscal year 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +21.5% in Total Revenue compared to the prior fiscal year.
- Harmony Biosciences Holdings, Inc. reported Revenue (ASC 606) of $868.45 million for fiscal year 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +21.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Harmony Biosciences Holdings, Inc. reported Net Income of $158.69 million for fiscal year 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +9.1% in Net Income compared to the prior fiscal year.
- Harmony Biosciences Holdings, Inc. reported Diluted EPS of $2.71 per share for fiscal year 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +8.0% in Diluted EPS compared to the prior fiscal year.
- Harmony Biosciences Holdings, Inc. reported Total Assets of $1.27 billion for fiscal year 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +27.3% in Total Assets compared to the prior fiscal year.
- Harmony Biosciences Holdings, Inc. reported Cash and Equivalents of $752.50 million for fiscal year 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +66.1% in Cash and Equivalents compared to the prior fiscal year.
- Harmony Biosciences Holdings, Inc. reported Long-Term Debt of $143.66 million for fiscal year 2025.
- Harmony Biosciences Holdings, Inc. showed a decrease of -11.9% in Long-Term Debt compared to the prior fiscal year.
- Harmony Biosciences Holdings, Inc. reported Stockholders Equity of $870.22 million for fiscal year 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +32.0% in Stockholders Equity compared to the prior fiscal year.
- Harmony Biosciences Holdings, Inc. reported R&D Expense of $189.59 million for fiscal year 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +30.0% in R&D Expense compared to the prior fiscal year.
- Harmony Biosciences Holdings, Inc. reported Operating Income of $208.47 million for fiscal year 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +9.2% in Operating Income compared to the prior fiscal year.
- Harmony Biosciences Holdings, Inc. reported Gross Profit of $670.11 million for fiscal year 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +20.1% in Gross Profit compared to the prior fiscal year.
- Harmony Biosciences Holdings, Inc. reported Shares Outstanding of 57.73 million shares for fiscal year 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +1.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: